# The Pharmacokinetics (PK), Pharmacodynamics(PD), Safety, Tolerability of SR1375 in Healthy Volunteers

> **NCT05421923** · PHASE1 · COMPLETED · sponsor: **Shanghai SIMR Biotechnology Co., Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** SR1375 capsules
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05421923
- **Lead sponsor:** Shanghai SIMR Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-24
- **Primary completion:** 2022-10-05
- **Final completion:** 2022-10-05
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05421923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05421923, "The Pharmacokinetics (PK), Pharmacodynamics(PD), Safety, Tolerability of SR1375 in Healthy Volunteers". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT05421923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*